Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DxNA to Acquire PathoGene

Published: Monday, July 22, 2013
Last Updated: Monday, July 22, 2013
Bookmark and Share
DxNA will acquire exclusive rights for Unit Dose Platform Applications of PathoGene’s multiplexed Staphylococcus MRSA+ assay on DxNA’s Real Time PCR GeneSTAT platform.

Terms of the agreement include upfront and milestone payments as well as ongoing royalties. In addition to the License Agreement, the two companies have agreed to a Letter of Intent under which DxNA would acquire PathoGene. This transaction is expected to occur in the next 6 months, contingent on satisfactory completion of due diligence and other contingencies. Financial terms contained in the LOI were not disclosed.

Pathogene’s next generation Staphylococcus assay is clearly differentiated from current commercially available MRSA assays in that it provides rapid identification and drug resistance information for Staphylococcus infections, one of the most common hospital acquired infections. In combination with the GeneSTAT platform, this capability can be delivered to almost any healthcare setting due to its portability and “point of care” design. “In addition to testing for MRSA, Pathogene’s assay also detects multi-drug resistant Coagulase Negative Staphylococcus strains, which are actually much more common infections than MRSA. This is a significant step forward compared to current diagnostic methods and allows the assay to rapidly identify and differentiate three of the most common pathogens of hospital acquired infections – surgical site infections, medical device infections and skin and soft tissue infections – in a single multiplexed assay. This provides information to physicians in about an hour that is critical to treatment decisions that save lives, improve patient outcomes and reduce treatment costs.” said Todd Snowden, PathoGene President and CEO.

”Pathogene’s novel approach with this Staph assay provides rapid clinical answers that impact patient care, costs and outcomes making the assay an ideal complement to our GeneSTAT platform. The use of the assay for diagnostics represents a combined $650M market opportunity in the US and the EU”, said David Taus, DxNA President and CEO.

DxNA’s Real Time PCR GeneSTAT platform for molecular diagnostic infectious disease testing is uniquely postioned to meet the on-site Staph diagnostic testing needs of Hospitals, Point of Care, Long Term Care and Urgent Care Centers. The GeneSTAT analyzer with the Staph multiplexed test cartridge provides the performance, ease of use, speed, portability and economics required for Staph diagnostic testing to be broadly adopted in these clinical settings.

DxNA LLC is a privately owned Limited Liability Company located in St. George, Utah. DxNA develops and commercially manufactures molecular-based diagnostic assays formatted in a unique and proprietary test cartridge designed for analysis by its proprietary GeneSTAT® analyzer. The test cartridges, together with the GeneSTAT analyzer make up DxNA’s proprietary GeneSTAT® Platform. The current assays are both DNA- and/or RNA-based “multiplexed” tests for “real time” detection of infectious disease agents in humans, and animals or of biological contaminants in the environment. DxNA combines proprietary intellectual property with industry proven technology into the GeneSTAT Platform that the Company believes to be unique in the industry. The GeneSTAT offers unmatched simplicity and control in the processing of specimens. The Platform is comprised of an analyzer and a single-use test cartridge, and can be run with minimal training in either laboratory or field settings accepting a number of specimen types.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
World-First Blood Test For Parkinson's
La Trobe University researchers have developed a world-first diagnostic blood test which could change the lives of people with Parkinson's disease.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Hepatitis C Virus Testing Guidelines Miss Too Many Cases
Urban emergency departments a good place to enact universal screening for adults.
NIH Sequences Genome of a Fungus
Researchers at the Institute have sequenced genome of human, mouse and rat Pneumocystis that cause life-threatening Pneumonia in immunosuppressed hosts.
Antibiotic Resistance Mechanism Continues to Spread
A recently discovered genetic mechanism allowing bacteria to develop and transfer resistance to colistin, one of the last-resort antibiotics, has been present in many countries across the world for more than a decade, according to late-breaking data presented at ECCMID.
Promising New Method Inhibits TB-Causing Bacteria
Researchers at UQ and UC San Francisco have found a new way to inhibit the growth of the bacterium that causes tuberculosis.
Liquid Biopsy for NSCLC
'Liquid biopsy' blood test accurately detects key genetic mutations in most common form of lung cancer, study finds.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!